http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006527732-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-273 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-10 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B61-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-273 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 |
| filingDate | 2004-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006527732-A |
| titleOfInvention | 3-sulfonylamino-pyrrolidin-2-one derivatives as inhibitors of factor XA |
| abstract | The present invention relates to a compound of formula (I): [Where: R 1 is: (Each ring may contain additional heteroatoms N; Z is an optional substituent halogen; alk is alkylene or alkenylene; T is S, O or NH) A group selected from: R 2 is hydrogen, —C 1-6 alkyl, —C 1-3 alkyl CONR a R b , —C 1-3 alkylCO 2 C 1-4 alkyl, —CO 2 C 1-4 alkyl or —C 1 -3 alkyl CO 2 H; R a and R b are independently hydrogen, —C 1-6 alkyl, or may be substituted by C 1-4 alkyl together with the N atom to which they are attached. Forming a 5-, 6- or 7-membered non-aromatic heterocyclic ring, which may contain additional heteroatoms selected from O, N or S, wherein S heteroatoms are O May be substituted by, i.e. S (O) n ; n is 0-2; X is halogen, —C 1-4 alkyl, —C 2-4 alkenyl, —CN, —CF 3 , —NR a R b , —C 0-4 alkyl OR e , —C (O) R f and —. Containing 5 or at least one heteroatom selected from phenyl, or O, N or S, optionally substituted by 0 to 2 groups selected from C (O) NR a R b A 6-membered aromatic heterocyclic group; R e is hydrogen or —C 1-6 alkyl; R f is —C 1-6 alkyl; Y is a —C (R x ) (R z ) C 0-2 alkyl NR c R d group; R x is C 1-4 alkyl optionally substituted by halogen; R z is C 1-4 alkyl optionally substituted by hydrogen or halogen; R c and R d are independently hydrogen, —C 1-6 alkyl, —C 1-4 alkyl OH, or together with the N atom to which they are attached, 4, 5, Forming a 6- or 7-membered non-aromatic heterocyclic ring, wherein the 5-, 6- or 7-membered non-aromatic heterocyclic ring may be substituted by C 1-4 alkyl, O, N or It may further contain a heteroatom selected from S] Or a pharmaceutically acceptable derivative thereof. Further, a method for producing a compound represented by the formula (I), a pharmaceutical composition containing the compound represented by the formula (I) and a pharmaceutical, particularly a formula (I used for improving clinical symptoms involving a factor Xa inhibitor ). |
| priorityDate | 2003-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 313.